549 related articles for article (PubMed ID: 30213652)
1. Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
Brain Behav Immun; 2018 Nov; 74():205-212. PubMed ID: 30213652
[TBL] [Abstract][Full Text] [Related]
2. The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway.
Guloksuz S; Arts B; Walter S; Drukker M; Rodriguez L; Myint AM; Schwarz MJ; Ponds R; van Os J; Kenis G; Rutten BP
Brain Behav Immun; 2015 Aug; 48():48-52. PubMed ID: 25765557
[TBL] [Abstract][Full Text] [Related]
3. Preliminary comparative analysis of kynurenine pathway metabolites in chronic ketamine users, schizophrenic patients, and healthy controls.
Zhang Z; Zhang M; Luo Y; Ni X; Lu H; Wen Y; Fan N
Hum Psychopharmacol; 2020 Jul; 35(4):e2738. PubMed ID: 32352599
[TBL] [Abstract][Full Text] [Related]
4. Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Ning Y
Psychoneuroendocrinology; 2019 Mar; 101():72-79. PubMed ID: 30419374
[TBL] [Abstract][Full Text] [Related]
5. Kynurenine pathway changes in late-life depression.
Wu Y; Zhong X; Mai N; Wen Y; Shang D; Hu L; Chen B; Zhang M; Ning Y
J Affect Disord; 2018 Aug; 235():76-81. PubMed ID: 29655078
[TBL] [Abstract][Full Text] [Related]
6. Kynurenine pathway changes in late-life depression with memory deficit.
Wu Y; Mai N; Zhong X; Wen Y; Zhou Y; Li H; Shang D; Hu L; Chen X; Chen B; Zhang M; Ning Y
Psychiatry Res; 2018 Nov; 269():45-49. PubMed ID: 30145300
[TBL] [Abstract][Full Text] [Related]
7. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
[TBL] [Abstract][Full Text] [Related]
8. Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.
Birner A; Platzer M; Bengesser SA; Dalkner N; Fellendorf FT; Queissner R; Pilz R; Rauch P; Maget A; Hamm C; Herzog-Eberhard S; Mangge H; Fuchs D; Moll N; Zelzer S; Schütze G; Schwarz M; Reininghaus B; Kapfhammer HP; Reininghaus EZ
PLoS One; 2017; 12(2):e0172699. PubMed ID: 28241062
[TBL] [Abstract][Full Text] [Related]
9. Predictors of response to repeated ketamine infusions in depression with suicidal ideation: An ROC curve analysis.
Zhou Y; Liu W; Zheng W; Wang C; Zhan Y; Lan X; Zhang B; Zhang C; Ning Y
J Affect Disord; 2020 Mar; 264():263-271. PubMed ID: 32056760
[TBL] [Abstract][Full Text] [Related]
10. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
Doolin K; Allers KA; Pleiner S; Liesener A; Farrell C; Tozzi L; O'Hanlon E; Roddy D; Frodl T; Harkin A; O'Keane V
Psychoneuroendocrinology; 2018 Sep; 95():8-17. PubMed ID: 29787958
[TBL] [Abstract][Full Text] [Related]
11. The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response.
Kadriu B; Farmer CA; Yuan P; Park LT; Deng ZD; Moaddel R; Henter ID; Shovestul B; Ballard ED; Kraus C; Gold PW; Machado-Vieira R; Zarate CA
Mol Psychiatry; 2021 Aug; 26(8):4085-4095. PubMed ID: 31732715
[TBL] [Abstract][Full Text] [Related]
12. Altered kynurenine pathway metabolites in serum of chronic migraine patients.
Curto M; Lionetto L; Negro A; Capi M; Fazio F; Giamberardino MA; Simmaco M; Nicoletti F; Martelletti P
J Headache Pain; 2015; 17():47. PubMed ID: 27130315
[TBL] [Abstract][Full Text] [Related]
13. Changes in tryptophan and kynurenine pathway metabolites in the blood of children treated with ketogenic diet for refractory epilepsy.
Żarnowska I; Wróbel-Dudzińska D; Tulidowicz-Bielak M; Kocki T; Mitosek-Szewczyk K; Gasior M; Turski WA
Seizure; 2019 Jul; 69():265-272. PubMed ID: 31129366
[TBL] [Abstract][Full Text] [Related]
14. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
[TBL] [Abstract][Full Text] [Related]
15. Kynurenine pathway in depression: A systematic review and meta-analysis.
Ogyu K; Kubo K; Noda Y; Iwata Y; Tsugawa S; Omura Y; Wada M; Tarumi R; Plitman E; Moriguchi S; Miyazaki T; Uchida H; Graff-Guerrero A; Mimura M; Nakajima S
Neurosci Biobehav Rev; 2018 Jul; 90():16-25. PubMed ID: 29608993
[TBL] [Abstract][Full Text] [Related]
16. A validated liquid chromatography-high resolution-tandem mass spectrometry method for the simultaneous quantitation of tryptophan, kynurenine, kynurenic acid, and quinolinic acid in human plasma.
Arnhard K; Pitterl F; Sperner-Unterweger B; Fuchs D; Koal T; Oberacher H
Electrophoresis; 2018 May; 39(9-10):1171-1180. PubMed ID: 29327354
[TBL] [Abstract][Full Text] [Related]
17. Altered serum levels of kynurenine metabolites in patients affected by cluster headache.
Curto M; Lionetto L; Negro A; Capi M; Perugino F; Fazio F; Giamberardino MA; Simmaco M; Nicoletti F; Martelletti P
J Headache Pain; 2015; 17(1):27. PubMed ID: 27000870
[TBL] [Abstract][Full Text] [Related]
18. The kynurenine pathway in major depressive disorder under different disease states: A systematic review and meta-analysis.
Ou W; Chen Y; Ju Y; Ma M; Qin Y; Bi Y; Liao M; Liu B; Liu J; Zhang Y; Li L
J Affect Disord; 2023 Oct; 339():624-632. PubMed ID: 37467793
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder.
Savitz J; Dantzer R; Wurfel BE; Victor TA; Ford BN; Bodurka J; Bellgowan PS; Teague TK; Drevets WC
Psychoneuroendocrinology; 2015 Feb; 52():200-11. PubMed ID: 25486577
[TBL] [Abstract][Full Text] [Related]
20. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.
Wichers MC; Koek GH; Robaeys G; Verkerk R; Scharpé S; Maes M
Mol Psychiatry; 2005 Jun; 10(6):538-44. PubMed ID: 15494706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
